Studies in burns: XV. Use of a topical lipid in treating human burns.
Sixty patients were selected from the 24-month burn population admitted to the Medical College of Georgia. Selection was on the basis of age, size of burn, and survival beyond 120 hours. Thirty-one of these patients were treated with ethyl linoleate agent (hELate) in addition to the modalities we routinely use for burn care. hELate was applied in a dose of 25 mg/kg only once in the period after burn. Significant pain relief and enhancement of wound healing (with return of hair and pigment) occurred in the hELate-treated patient. Less narcotic was needed, fewer grafts and reconstructive procedures were required, and hospital stay was reduced significantly. It is suggested that hELate is a safe and useful adjunctive to burn care.
D000287:Administration, Topical; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001753:Blast Injuries / Q000188:drug therapy; D002056:Burns / Q000188:drug therapy* / Q000601:surgery; D002057:Burns, Chemical / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003646:Debridement; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008041:Linoleic Acids / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D011182:Postoperative Care; D016038:Skin Transplantation; D014182:Transplantation, Autologous; D014945:Wound Healing / Q000187:drug effects
D000900:Anti-Bacterial Agents; D008041:Linoleic Acids